We previously reported that tumor vaccination plus anti-CTLA-4 antibody was surprisingly more effective in an aggressive mouse cell line (AgN2a) (90% cure) than in the wild-type Neuro2a cell line (60% cure) [14]. This evidence concerns the gene CTLA4 and neoplasm.